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We recently identified a new acute myeloid leukemia (AML)
subtype characterized by mutations at exon-12 of the nucleo-
phosmin (NPM) gene and aberrant cytoplasmic expression of
NPM protein (NPMcþ ). NPMcþ AML accounts for about 35% of
adult AML and it is associated with normal karyotype, wide
morphological spectrum, CD34-negativity, high frequency of
FLT3-ITD mutations and good response to induction therapy. In
an attempt to identify a human cell line to serve as a model for
the in vitro study of NPMcþ AML, we screened 79 myeloid cell
lines for mutations at exon-12 of NPM. One of these cell lines,
OCI/AML3, showed a TCTG duplication at exon-12 of NPM. This
mutation corresponds to the type A, the NPM mutation most
frequently observed in primary NPMcþ AML. OCI/AML3 cells
also displayed typical phenotypic features of NPMcþ AML, that
is, expression of macrophage markers and lack of CD34, and
the immunocytochemical hallmark of this leukemia subtype,
that is, the aberrant cytoplasmic expression of NPM. The
OCI/AML3 cell line easily engrafts in NOD/SCID mice and
maintains in the animals the typical features of NPMcþ AML,
such as the NPM cytoplasmic expression. For all these reasons,
the OCI/AML3 cell line represents a remarkable tool for bio-
molecular studies of NPMcþ AML.
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Introduction
Acute myeloid leukemia (AML) is clinically and molecularly
heterogeneous.1 About 40–50% of adult AMLs show normal
karyotype2 and their clinical and biological features are poorly
understood.1,3
We identified mutations at exon-12 of the nucleophosmin
(NPM) gene as the genetic lesion most specifically and
frequently associated with normal karyotype in adult4 and
pediatric5 AML. Named NPMcþ AML, this subgroup accounts
for about 35% of adult AML (60% of all AML with normal
karyotype), encompasses all FAB/WHO categories6 except M3,
M4eo and M7 and is characterized by multilineage involve-
ment, CD34-negativity, high frequency of FLT3 mutations and
good response to induction therapy.4
Exon-12 NPM gene mutations are AML-specific since they are
not detected in normal cells or other neoplasms. Frameshifts
alter NPM protein at its C-terminus4 and the mutated NPM
protein localizes aberrantly in leukemic cell cytoplasm,4 while
wild-type NPM, a protein with multiple functional domains,7
shuttles between nucleus and cytoplasm,8 and is found mainly
in the nucleolus.9
The mechanisms underlying abnormal cytoplasmic accumu-
lation of mutant NPM protein and its interference with wild-type
NPM, which is involved in ARF-p53 pathway regulation10–12
and centrosome duplication,13 remain to be clarified.
In an attempt to identify a human NPMcþ AML cell line,
which would greatly help in addressing these issues and in
investigating the activity of new drugs, we screened 79 myeloid
cell lines for the presence of exon-12 NPM gene mutations and
found one, OCI/AML3, exhibiting the typical molecular and
biological features of NPMcþ AML.
Materials and methods
Mutational analysis of human myeloid cell lines
A total of 79 human myeloid cell lines were evaluated for NPM
mutations (Table 1). Mutations at the exon-12 of the NPM gene
are recurrent genetic aberrations in AML.4 The NPM mutated
and wild-type status of the 79 cell lines was verified by
determining the size of the products of an NPM polymerase
chain reaction (PCR) by capillary gel electrophoresis. NPM PCR
analysis was performed with a DNA thermal cycler (Perkin
Elmer Cetus, Heidelberg, Germany) under the following
conditions: 30 s at 941C for denaturation, 30 s at 531C for
annealing and 2 min at 721C for extension. Genomic PCR
amplification was performed using primer NPM intron 11
forward: 50-TTA ACT CTC TGG TGG TAG AAT GAA-30 and
reverse-transcriptase PCR with primer NPM exon 11 forward:
50-CAT CAA TTA TGT GAA GAA TTG CTT-30. Reverse primer
for both PCR analyses was NPM exon 12 reverse: 50-TGT TAC
AGA AAT GAA ATA AGA CGG-30. The reverse primer was
either labeled with the fluorescent dye D4 (for capillary
electrophoresis) or not-labeled (for cloning experiments).
Oligonucleotides were obtained from Proligo (Paris, France).
For fragment size determination, 1ml of the PCR products was
combined with 0.25ml of an internal size standard (size standard
kit 400, Beckman-Coulter, Krefeld, Germany) in a total volume
of 30 ml sample loading solution (SLS, Beckman-Coulter).
Electrophoresis was carried out on the capillary electrophoresis
system CEQ 8000 (Beckman-Coulter). The following injection
and electrophoretic running conditions were used: 0.5 ml sample
injection, 5 min DNA strand denaturation at 931C, separation at
6000 V at 501C and signal detection with calibrated D4
emission spectra. Fragment size determinations were performed
using default fragment analysis parameters of the CEQ 8000
fragment analysis software, allowing the precise determination
of fluorescent DNA fragments resulting in an electropherogram
and a fragment summary list. NPMwt PCR products were 215 bp
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(genomic PCR) and 139 bp (RT-PCR). NPMm primary AML cells,
used as positive control, exhibited 4 bp larger signals in addition
to the NPMwt signals. For the identification of NPM variants in
cell lines, a second PCR analysis was performed, this time with
unlabeled oligonucleotides. The PCR products were cloned
into the pGEM-T Easy Vector System (Promega, Mannheim,
Germany), NPMm and wt clones were identified with the
described detection system and positively identified plasmids
were sequenced (MWG Biotech, Ebersberg, Germany).
Cytogenetic analysis
Karyotypic analysis and fluorescence in situ hybridization (FISH)
were performed as described previously14
Antibodies
Monoclonal anti-NPM and anti-CD68 antibodies have been
previously described.9,15,16 An affinity-purified rabbit polyclonal
antibody (SIL-A) was generated against a synthetic 18mer
peptide (NH2-QEAIQDLCLAVEEVSLRK-COOH) (Primm srl,
Milan, Italy), which recognizes the NPM mutant A4 but not
wild-type NPM protein. Monoclonal antibody against nucleolin
(C23) was purchased from Dako Cytomation (Glostrup,
Denmark).
Engraftment in NOD/SCID mice
NOD/SCID mice were purchased from Charles River Italia Spa
(Calco, Italy) and maintained under sterile conditions in the
animal facilities at the University of Perugia, Perugia, Italy. Six
mice were injected subcutaneously with OCI/AML3 cells at
dosage ranging from 20 106 to 50 106 OCI/AML3 cells.
Immunocytochemical detection of NPM
For immuno-alkaline phosphatase (APAAP) detection of wild-
type and mutant NPM proteins, we used cytocentrifuge
preparations of acetone- or 4% paraformaldeyde-fixed (10 min)
OCI/AML3 cells, and paraffin sections (3 mm) from B5-fixed cell
line pellets (each containing 107 cells). Paraffin sections were
subjected to antigen retrieval by microwaving in 0.1 mM EDTA
pH 8.0.4 The immuno-alkaline phosphatase APAAP technique
was used for immunostaining.17
Table 1 Human myeloid cell lines screened for exon-12 NPM
gene mutations
Cell line FAB DSM ACC
AML-14 M2
AML-193 M5 549
AS-E2 M6
CHRF-288-11 M7
CMK M7 392
CMY M7
CTS M1
CTV-1 M5 40
ELF-153 M7
EOL-1 eosino 386
F-36P M6 543
FKH-1 M4
GDM-1 M4 87
GF-D8 M1
HEL M6 11
HL-60 M2 3
HNT-34 M4
HT-93A M3
HU-3 M7
IMS-M1 M5
K-051 M2
KASUMI-1 M2 220
KASUMI-3 M0
KBM-3 M4
KG-1 NI 14
KMOE-2 M6 37
KP-MO-TS M5
KY-821 M2
M-07e M7 104
MARIMO M2
MB-02 M7
ME-1 M4 537
MEGAL M7
MKPL-1 M7
ML-2 M4 15
MML-1 M1
M-MOK M7
MOLM-13 M5 554
MOLM-16 M0 555
MOLM-17 sAML
MONO-7 M0
MONO-MAC-6 M5 124
MR-87 NI
MUTZ-2 M2 271
MUTZ-3 M4 295
MUTZ-8 M4
MUTZ-11 M4
MV4;11 M5 102
NB-4 M3 207
NOMO-1 M5 542
OCI-AML-1 M4
OCI-AML-2 M4 99
OCI-AML-3 M4 582
OCI-AML-4 M4
OCI-AML-5 M4 247
OCI-AML-6 M4
OCI-M1 M6 529
OCI-M2 M6
OHN-GM tAML
OMA-AML-1 M4
PL-21 M3 536
SAML-2 tAML
SIG-M5 M5 468
SKM-1 M5 547
SKNO-1 M2
TF-1 M6 334
THP-1 M5 16
TK-1B M4
TMD-7 M7
TSU-1621MT M4
U-937 M5 5
UCSD/AML1 NI
UF-1 M3
UG-3 M5
UOC-M1 M1
UT-7 M7 137
YK-M2 M5
YNH-1 M1
X-376 NI
DSM ACC, cell line available from DSMZ cell lines bank
(www.dsmz.de); FAB, French–American–British classification system;
NI, not indicated; sAML, secondary AML; tAML, therapy-related AML.
Table 1 (Continued).
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For immunofluorescence, paraffin sections of OCI/AML3 cells
were incubated with the anti-NPM monoclonal antibody9,15
followed by a secondary goat anti-mouse antibody conjugated
with Alexa 488 (Molecular Probes, OR, USA), counterstained
with propidium iodide and analyzed with a confocal micro-
scope (Zeiss, LSM 510). Images were collected with a Zeiss LSM
510 confocal microscope Carl Zeiss, Jena, DE, Germany) using
the 488 nm (for Alexa 488) and the 543 nm (for propidium
iodide) laser lines for excitation. AOTF-controlled tuning of laser
lines, diameters of pinholes and light collection configuration
were optimized to obtain the best signal-to-noise ratio and to
avoid any fluorescence crossover.
The LSM 510 software was used for microscope regulation
and collection of images. The images were transferred to an SGI
Octane workstation (Silicon Graphics, Mountain View, CA,
USA) for further processing. Three-dimensional reconstruction
of the slices was performed with the shadow technique, using
the Imaris (Bitplane, Zurich, CH) software.
Western blotting
Nuclear and cytoplasmic extracts were prepared using a slightly
modified Schreiber method.18 Briefly, 5 106 cells were
collected, washed with phosphate-buffered saline and used
either fresh or after being snap frozen in liquid nitrogen. Either
cells or frozen cell pellets were resuspended in 150 ml of buffer
A containing 10 mmol/l HEPES (pH 7.9), 1.5 mmol/l MgCl2,
10 mmol/l KCl, 0.2 mmol/l EDTA, 1 mmol/l dithiothreitol and
proteases inhibitors (2mg/ml aprotinin, 2mg/ml leupeptin, 1 mM
phenylmethane sulfonyl fluoride, 1 mM sodium orthovanadate)
and incubated for 15 min on ice, after which 7.5 ml of a 10%
solution of Nonidet P-40 (0.5%, final) was added and the tube
was vigorously vortexed for 10 s. The homogenate was
centrifuged at 12 000 r.p.m for 30 s. The cytoplasmic super-
natant fraction was spun once more to ensure complete removal
of nuclei. The nuclear pellet was washed again with buffer A
with centrifugation as above. The nuclear pellet was then
resuspended in 50 ml of lysis buffer C containing 10 mmol/l
HEPES (pH 7.9), 0.42 mol/l NaCl, 1.5 mmol/l MgCl2, 0.2 mmol/l
EDTA, 0.5 mmol/l dithiothreitol, 25% glycerol and proteases
inhibitors. After incubation on ice for 15 min (with occasional
vortexing) the samples were centrifuged at 12 000 r.p.m for
15 min at 41C. The supernatant was recovered as nuclear
extracts. Nuclear and cytoplasmic extracts were snap frozen in
liquid nitrogen and stored at 801C until use.
Whole cell lysates (WCL) were prepared by addition of ice-
cold lysis buffer (1% NP-40, 150 mmol/l NaCl, 25 mmol/l Tris
pH 7.5, 1 mmol/l EDTA, 1 mmol/l Na3VO4, 1 mg/ml leupeptin,
1mg/ml aprotinin, and 1 mmol/l phenylmethylsulfonyl fluoride)
on ice for 20 min. Cell lysates were clarified by centrifugation at
14 000 g for 10 min at 41C. Proteins were boiled in SDS sample
buffer, separated by SDS-polyacrylamide gel electrophoresis
(SDS-PAGE), transferred to polyvinylidene difluoride (PVDF;
Millipore, Bedford, MA, USA) and probed with primary
antibodies followed by horseradish peroxidase-conjugated
secondary antibodies. Polypeptides recognized in the Western
blot were detected using the enhanced chemiluminescence
(ECL) methods according to the manufacturer’s instructions
(Amersham Pharmacia Biotech Inc., Piscataway, NJ, USA).
Figure 1 The OCI/AML3 cell line carries mutation A at exon-12 of the NPM gene. (a) Electropherogram of NPM RT-PCR of cell line
OCI/AML3. Cell line OCI/AML3 expresses wild-type (139 bp) and mutant (143 bp) version of the NPM gene. (b) (left) Morphological appearance of
OCI/AML3 cells (May Gru¨nwald Giemsa;  1000); (right) the OCI/AML3 cells express the macrophage-restricted CD68 (monoclonal antibody
PG-M1; APAAP technique; 1000).
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Results
OCI/AML3 cell line bears mutation A at exon-12 of the
NPM gene
OCI/AML3 was the only myeloid cell line among the 79 tested
that expressed a signal in addition to and 4 bp larger than the
wild-type NPM signal (Figure 1a). Sequencing of cloned NPM-
mutated PCR product showed TCTG duplication at positions
956–959 of exon-12 of the reference sequence (GenBank
accession number NPM-002520). This mutation was hetero-
zygous and corresponded to the type A we previously described
in 77% of primary NPMcþ AMLs.4 Exon-12 NPM mutation of
type A causes a frameshift in the region encoding the C-terminal
of the NPM protein. As a consequence, the last seven amino
acids (WQWRKSL) of NPM are replaced by 11 different residues
(CLAVEEVSLRK). Important changes at the C-terminus of NPM
mutant A include mutations of both tryptophans at position 288
and 290 which are important for nucleolar localization19 and
the creation of an NES motif.20
Phenotypic and cytogenetic/FISH features of the
OCI/AML3 cell line
The OCI/AML3 cell line was established from the peripheral
blood taken from a 57-year-old male with AML FAB-M4.21 The
OCI/AML3 cells show a myeloid morphology (Figure 1b, left-
hand side) and the immunophenotype: CD3, CD4þ , CD8,
CD10, CD13þ , CD14, CD15þ , CD19, CD30, CD34,
CD41þ , CD42b, CD68þ (Figure 1b, right-hand side), CD117
and CD235aþ .
Karyotype of the AML at diagnosis from which OCI/AML3 was
established was not available. The consensus karyotype was
48(45-50)o2n4X/XY,þ 1,þ 5,þ 8, der(1)t(1;18) (p11;q11),i(5p),
del(13)(q13q21),dup(17)(q21q25);sdl with r(Y)x1-2;hemizygous
for RB1 (Figure 2).
FISH analysis of OCI/AML3 revealed no structural rearrange-
ments involving MLL, MOZ, or CBFB. FLT3 internal tandem
duplication (ITD) is a recurrent aberration in AML,22 but quite
rare in cell lines.23 Although FTL3 ITD are twice as frequent in
NPMcþ than in NPMc AML with normal karyotype,4 the cell
line OCI/AML3 exhibits neither FLT3 ITD nor FLT3 D835 point
mutation.23
OCI/AML3 cell line exhibits aberrant cytoplasmic
NPM expression
Immunostaining with specific monoclonal antibodies9 detected
NPM both in the cytoplasm and nucleus (nucleoli) of OCI/AML3
cells (Figure 3a, top left, middle left). This contrasts with the
nucleus-restricted expression of NPM observed in AMLs bearing
wild-type NPM, such as the cell line HL-60 (Figure 3a, top right).
Therefore, the NPM staining pattern in the OCI/AML3 cell line is
identical to that observed in primary NPMcþ AML samples.4
However, anti-NPM monoclonal antibodies do not distin-
guish between wild-type and mutated NPM which are both
Figure 2 Karyotype of the OCI/AML3 cell line. Representative metaphase cell harvested from OCI/AML3 cultures. Note the presence of
an additional copy of an isochromosome for the short arms of chromosome 5 and trisomy 8, together with a partial trisomy of chromosome 1
as described for a distinct subgroup of AML patients.25 Abnormal chromosomes are indicated by arrows. Rearrangements were confirmed by
locus-specific FISH.
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present in leukemic cells due to the fact that exon-12 NPM
mutations are consistently heterozygous.4 In order to investigate
the subcellular expression of the mutant A without the
interference of the NPM wild-type protein, we stained the
OCI/AML3 cells with an antibody specific for mutant A and
found that mutated NPM is expressed exclusively in the cyto-
plasm (Figure 3a, middle right); pre-incubation with the immuno-
gen peptide abolished the reactivity of the anti-NPM-mutated
Figure 3 The NPM mutant protein A shows a cytoplasmic-restricted expression in OCI/AML3 cells. (a) (Top left) Immunofluorescence analysis
with an anti-NPM monoclonal antibody shows NPM in the cytoplasm and nucleoli of OCI/AML3 cells (nuclei are counterstained in red with
propidium iodide). (Top right) The same antibody recognizes NPM exclusively in the nucleoli of HL-60 cells that bear only wild-type NPM.
(Middle left) Monoclonal antibody anti-NPM labels the wild-type NPM protein in the nucleus and the mutated NPM protein in the cytoplasm of the
OCI/AML3 cells. (Middle right) The SIL-A antibody identifies the NPM mutant A (NPMm) as exclusively expressed in the cytoplasm of the
OCI/AML3 cells. (Bottom left) Incubation of the SIL-A antibody with the 18mer immunogen peptide abolishes the cytoplasmic reactivity
confirming the specificity of the antibody. (Bottom right) Expression of nucleolin (C23) is restricted to the nucleus (mainly nucleoli) of OCI/AML3
cells. (b) Western blotting: The antibody specific for the mutated NPM protein (anti-NPMm, SIL-A) identifies a band of the expected molecular
weight of NPM in the cytoplasmic (C) but not in the nuclear (N) fractions of the OCI/AML3 cells (left panel). In contrast, the anti-NPM monoclonal
antibody 376 (which cannot discriminate between wild-type and mutated NPM) recognizes the 37 kDa band both in the cytoplasmic and nuclear
fraction of the OCI/AML3 cells (right panel). The anti-NPMm, SIL-A antibody identifies the 37 kDa NPM band in whole lysates of NPMcþ AML
patients 1–3 bearing exon-12 NPM mutation but not in NPMc AML patients 5–6 bearing wild-type NPM (central panel). WCL indicates: whole-
cell lysates. NPMcþ indicates: NPM-cytoplasmic positive; NPMc indicates: NPM-cytoplasmic negative.
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antibody (Figure 3a, bottom left). In contrast, the anti-nucleolin
antibody only labeled nucleoli (Figure 3a, bottom right).
Immunohistochemical findings were confirmed by Western
blotting analysis (Figure 3b).
Alltogether, these findings demonstrate that OCI/AML3 cells
bear the hallmark of primary NPMcþ AML, that is mislocaliza-
tion of the mutant NPM protein in the cytoplasm.
Engraftment in NOD/SCID mice
Subcutaneous injection of OCI/AML3 cells in NOD/SCID
produced palpable tumors in all six injected animals by days
25–30. At post-mortem examination, mice showed dissemi-
nated disease that was confirmed by morphological and
immunohistochemical studies showing the typical aberrant
expression of NPM in the cytoplasm of the leukemic cells
(Figure 4). Since the anti-NPM monoclonal antibodies recognize
both human and mouse NPM, nucleus-restricted expression of
murine NPM served as a control.
Discussion
Human cell lines derived from AML bearing recurrent chromo-
somal abnormalities represent remarkable tools for biological
and molecular studies of these diseases.14
We recently identified a new AML subtype characterized by
mutations at exon-12 of the NPM gene and aberrant cytoplasmic
expression of the NPM protein (NPMcþ ).4 NPMcþ AML
accounts for about 35% of adult AML and it is characteristically
associated with a normal karyotype, wide morphological
Figure 4 Engrafment of the OCI/AML3 cells in NOD/SCID mice. (Top left) Infiltration of muscle (asterisk) by OCI/AML3 cells (Hematoxylin–
Eosin; 800); (top right) OCI/AML3 cells infiltrating the muscle (asterisk) express the human CD45 antigen ( 400); (middle left) bone marrow
involvement by OCI/AML3 cells expressing cytoplasmic nucleophosmin (double arrow); the single arrow points to a residual mouse
megakaryocyte showing the expected nucleus-restricted expression of NPM (800); (middle right) OCI/AML3 cells infiltrating the marrow show
nucleus-restricted expression of nucleolin/C23 (arrowhead); a residual mouse megakaryocyte (arrow) is not labeled by the anti-human nucleolin
(C23) monoclonal antibody (800); (bottom left) liver infiltration by OCI/AML3 expressing cytoplasmic NPM (arrow) (400); (bottom right) lung
infiltration by OCI/AML3 with cytoplasmic NPM (arrow); the asterix indicates a bronchiolar lumen (400). All immunostainings were performed
using APAAP technique.
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spectrum, CD34 negativity, high frequency of FLT3-ITD muta-
tions and a relatively good response to induction therapy.4 Our
numerous attempts to establish a cell line from these leukemic
patients were unsuccessful. This prompted us to carry out a
mutational screening for exon-12 NPM mutations in a large
number of available human myeloid cell lines.
Here, we report that the OCI/AML3 cell line bears the
characteristic molecular and biological features of the NPMcþ
AML. The OCI/AML3 cell line was the only human myeloid cell
line, among the 79 tested, to bear mutations at the exon-12 of
the NPM gene. As NPM mutations occur in about 35% of adult
AML patients,4 their low frequency in myeloid cell lines is
somewhat surprising, but may indicate this leukemia subtype is
difficult to grow in culture, possibly because of its dependence
on host growth factors. Notably, the OCI/AML3 cell line bears
mutation A, which is the most frequent type of mutations
occurring at exon-12 of the NPM gene in AML (about 80% of
cases).4 In this regard, OCI/AML3 is a model representative
of most patients with NPMcþ AML.
The immunophenotype of the OCI/AML3 cell line is also
consistent with a derivation from a patient with NPMcþ AML.
The OCI/AML3 cells express macrophage markers such as CD68
(PG-M1)16 and lack of CD34. This is in keeping with the finding
that primary NPMcþ AML are most frequently of the M4 and
M5 type and show absence of CD34 both at immunohisto-
chemistry4 and gene expression profiling.24
Mutations at exon-12 of the NPM gene are the genetic lesions
most specifically and frequently associated with normal
karyotype in adult AML.4 NPMcþ AML account for about
60% of all adult AML with a normal karyotype. Karyotype of
patient primary AML cells from which the OCI/AML3 was
established was not known. The results of our cytogenetic
investigations deserve some comments. Trisomy 8 occurs in
10–15% of AML in all FAB subgroups, alone or together with
simple karyopypic changes.22 Interestingly, þ 8 partners i(5p) in
a subset of AML-M5 patients, possibly associated with 1q
trisomy25 as found in OCI/AML3. This is in keeping with the
finding that NPMcþ AML are more frequent in M5 than
other FAB subtypes.4 Deletion of proximal 13q (including the
FLT3 locus at 13q13) as present in OCI/AML3 may also partner
þ 8 in AML patients possibly targeting loss of heterozygosity
affecting the RB1 locus at 13q14.26 The association in OCI/
AML3 of the above chromosomal abnormalities and NPM gene
mutation is not surprising since we previously reported that
about 14% of NPMcþ AML bear nonmajor chromosomal
abnormalities.4
The OCI/AML3 displays one of the most remarkable features
of NPMcþ AML, that is, the dislocation of the NPM protein in
the cytoplasm. According to our results, this finding is certainly
due to the presence in the cytoplasm of the NPM mutant A and,
possibly, of the wild-type NPM protein that could be aberrantly
recruited in the cytoplasm through formation of heterodimers
with the mutant.27 In contrast, we regard nuclear labeling of
OCI/AML3 for NPM to be exclusively due to the presence in that
site of the wild-type NPM protein, as proved by the finding that
an antibody specifically directed against the mutant only detects
the abnormal NPM protein in the cytoplasm. Mechanism of
altered-nucleo-cytoplasmic traffic of NPM in leukemic cells is
unknown and the OCI/AML3 represents a good in vitro model
for addressing this issue and analyzing the drug’s ability to
interfere with this process. Moreover, OCI/AML3 cells easily
engraft in NOD/SCID mice and this may serve as a pre-clinical
model for testing new therapeutic modalities.
In conclusion, the OCI/AML3 represents the only permanent
cell line sharing all molecular and biological features of primary
NPMcþ AML and emerges as a remarkable tool for studying
this new leukemia subtype.
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